Allianz Asset Management GmbH Raises Holdings in Organon & Co. $OGN

Key Points

• Allianz Asset Management GmbH increased its holdings in Organon & Co. by 4.2%, owning approximately 1,329,902 shares worth $12.87 million as of the latest SEC filing.
• Organon & Co. reported quarterly earnings of $1.00 per share, exceeding the consensus estimate of $0.94, with revenue of $1.59 billion.
• The stock has shown significant fluctuations, with a 12-month low of $8.01 and a high of $19.05, currently trading around $9.25.

Allianz Asset Management GmbH boosted its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 4.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,329,902 shares of the company's stock after buying an additional 53,653 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.51% of Organon & Co. worth $12,873,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Organon & Co. by 186.9% in the first quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock worth $69,000 after acquiring an additional 3,004 shares during the period. Janney Montgomery Scott LLC raised its holdings in Organon & Co. by 18.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 279,624 shares of the company's stock worth $4,164,000 after purchasing an additional 44,424 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in Organon & Co. by 67.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 54,165 shares of the company's stock worth $807,000 after purchasing an additional 21,887 shares in the last quarter. HBK Sorce Advisory LLC purchased a new stake in shares of Organon & Co. in the 1st quarter worth about $241,000. Finally, Sequoia Financial Advisors LLC boosted its stake in shares of Organon & Co. by 42.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock valued at $289,000 after purchasing an additional 5,758 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Performance

Shares of OGN stock opened at $9.25 on Tuesday. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The stock has a market cap of $2.40 billion, a PE ratio of 3.44, a price-to-earnings-growth ratio of 0.84 and a beta of 0.63. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The company's fifty day moving average price is $9.94 and its 200-day moving average price is $9.97.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same period last year, the business earned $1.12 EPS. Organon & Co.'s quarterly revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. On average, equities analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 15th. Organon & Co.'s dividend payout ratio (DPR) is presently 2.97%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (d+)" rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $17.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.